American Heart Journal
Volume 156, Issue 2, Supplement , Pages 23S-28S , August 2008

Clinical overview of promising nonthienopyridine antiplatelet agents

  • Dominick J. Angiolillo, MD, PhD, FACC, FESC

      Affiliations

    • Corresponding Author InformationReprint requests: Dominick J. Angiolillo, MD, PhD, FACC, FESC, Division of Cardiology, University of Florida–Shands Jacksonville, 655 West 8th St, Jacksonville, FL 32209.
    • ,
  • Luis A. Guzman, MD, FACC

References 

  1. Peters G, Robie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140—an oral reversible ADP receptor antagonist. [abstract] Haematologica. 2004;989(Suppl 7):14
  2. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–1047
  3. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non–ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–1851
  4. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852–1856
  5. Nassim MA, Sanderson JB, Clarke C, et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate–induced platelet aggregation and bleeding time in healthy volunteers. [abstract] J Am Coll Cardiol. 1999;33(2 Suppl A):255A
  6. Jarvis GE, Nassim MA, Humphries RG, et al. The P2T antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood. 1999;94(Suppl 1):22A
  7. Greenbaum AB, Ohman EM, Gibson MS, et al. Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction. J Am Coll Cardiol. 2002;39(Suppl):281A
  8. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85:401–407
  9. Jacobsson F, Swahn E, Wallentin L, et al. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non–Q-wave myocardial infarction. Clin Ther. 2002;24:752–765
  10. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13:407–413
  11. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151:689.e1–689.e10
  12. Angiolillo DJ, Fernandez-Ortix A, Bernanrdo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol. 2007;49:1505–1516
  13. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline?. Am J Cardiovasc Drugs. 2007;7:423–432
  14. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527–534
  15. Kosoglou T, Larisa Reyderman L, Robert R, et al. Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor (PAR-1) antagonist SCH 530348. [abstract] Circulation. 2005;112(Suppl):1–32
  16. Moliterno DJ, Becker RC, Jennings LK, et al. Results of a multinational randomized double-blind, placebo-controlled study of a novel thrombin receptor antagonist in percutaneous coronary intervention. In: Presented at the Late Breaking Clinical Trials at the American College of Cardiology Scientific Sessions, New Orleans, Louisiana, March 24-27. 2007;

 Conflicts of Interest: Dominick J. Angiolillo, MD, PhD, FACC, FESC has declared the following conflicts of interest: Honoraria/Lectures: Bristol Myers Squibb (New York, NY); Sanofi-Aventis (Bridgewater, NJ); Eli Lilly and Company (Indianapolis, IN); Daiichi Sankyo, Inc (Parsippany, NJ). Honoraria/Advisory board: Bristol Myers Squibb; Sanofi-Adventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company (Parsippany, NJ); Portola (San Francisco, CA); Novartis (East Hanover, NJ). Research Grants: GlaxoSmithKline (Brentford, London, United Kingdom); Otsuka (Tokyo, Japan). Luis A. Guzman, MD, FACC, has declared no conflicts of interest.

PII: S0002-8703(08)00473-0

doi: 10.1016/j.ahj.2008.06.006

American Heart Journal
Volume 156, Issue 2, Supplement , Pages 23S-28S , August 2008

Article Tools